This product has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, significantly promote expectoration, and improve respiratory conditions. When this product is used for treatment, the patient's mucus secretion can return to normal, cough and sputum volume are usually significantly reduced, and the surfactant on the respiratory mucosa can thus play its normal protective function. The toxicity index of ambroxol hydrochloride in acute toxicity tests is very low. The Ames test and micronucleus test show that ambroxol hydrochloride is not mutagenic. The carcinogenicity studies on mice and rats show that ambroxol hydrochloride is not carcinogenic.

Participate in cell energy metabolism and protein synthesis in the body, increase the activity of related metabolic enzymes, improve liver function, and promote the recovery of damaged liver

Inosine participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

Inosine participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

Inosine participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

Inosine participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

This product is an H2 receptor antagonist. It replaces the imidazole ring of cimetidine with a furan ring. It has a higher selectivity for H2 receptors and can significantly inhibit the basal and nocturnal gastric acid secretion of normal people and ulcer patients, as well as the gastric acid secretion caused by pentagastrin, histamine and meals. Its gastric acid inhibition effect is 5 to 12 times stronger than that of cimetidine. Intravenous injection of this product can reduce gastric acid secretion by 90%; it has a certain inhibitory effect on the secretion of pepsinogen. It has a protective effect on experimental gastric mucosal damage and acute ulcers. It has no effect on the secretion of gastrin and sex hormones.

The experiment was not conducted and there is no reliable reference

This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls. Its action characteristics vary depending on the type of bacteria. It has a high affinity with PBP1 (1a, 1b, 1c) and PBP3 among penicillin-binding proteins (PBP). This product has a strong stability against β-lactamases produced by various bacteria.